Comera Life Sciences Inc... (CMRA)
Comera Life Sciences Statistics
Share Statistics
Comera Life Sciences has 30.74M shares outstanding. The number of shares has increased by 0% in one year.
Shares Outstanding | 30.74M |
Shares Change (YoY) | 0% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 3.78% |
Shares Floating | 9.67M |
Failed to Deliver (FTD) Shares | - |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 281.55K, so 0.92% of the outstanding shares have been sold short.
Short Interest | 281.55K |
Short % of Shares Out | 0.92% |
Short % of Float | 6.44% |
Short Ratio (days to cover) | 0.84 |
Valuation Ratios
The PE ratio is -0.71 and the forward PE ratio is null. Comera Life Sciences's PEG ratio is 0.
PE Ratio | -0.71 |
Forward PE | n/a |
PS Ratio | 20.31 |
Forward PS | null |
PB Ratio | -2.06 |
P/FCF Ratio | -1.31 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Comera Life Sciences.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.61, with a Debt / Equity ratio of -0.12.
Current Ratio | 0.61 |
Quick Ratio | 0.61 |
Debt / Equity | -0.12 |
Debt / EBITDA | -0.04 |
Debt / FCF | -0.08 |
Interest Coverage | -587.02 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $52.76K |
Profits Per Employee | $-1.5M |
Employee Count | 12 |
Asset Turnover | 0.17 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -20.43, so Comera Life Sciences's price volatility has been lower than the market average.
Beta | -20.43 |
52-Week Price Change | null% |
50-Day Moving Average | 0 |
200-Day Moving Average | 0.01 |
Relative Strength Index (RSI) | 29.55 |
Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Comera Life Sciences had revenue of 633.1K and earned -18M in profits. Earnings per share was -1.76.
Revenue | 633.1K |
Gross Profit | 422.71K |
Operating Income | -11.97M |
Net Income | -18M |
EBITDA | -17.89M |
EBIT | -17.98M |
Earnings Per Share (EPS) | -1.76 |
Balance Sheet
The company has 446.61K in cash and 775.05K in debt, giving a net cash position of -328.44K.
Cash & Cash Equivalents | 446.61K |
Total Debt | 775.05K |
Net Cash | -328.44K |
Retained Earnings | -34.9M |
Total Assets | 3.07M |
Working Capital | -301.92K |
Cash Flow
In the last 12 months, operating cash flow was -9.77M and capital expenditures -28.61K, giving a free cash flow of -9.8M.
Operating Cash Flow | -9.77M |
Capital Expenditures | -28.61K |
Free Cash Flow | -9.8M |
FCF Per Share | -0.94 |
Margins
Gross margin is 66.77%, with operating and profit margins of -1890.69% and -2843.79%.
Gross Margin | 66.77% |
Operating Margin | -1890.69% |
Pretax Margin | -2843.79% |
Profit Margin | -2843.79% |
EBITDA Margin | -2825.23% |
EBIT Margin | -1890.69% |
FCF Margin | -1547.99% |
Dividends & Yields
CMRA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CMRA.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | -28.11 |
Piotroski F-Score | 2 |